N-Allylcyclohexylamine → N-Allyl-N-cyclohexyl-2-[4-(3,3-diphenyl-1-propyl)piperazin-1-yl]-5-methylisonicotinamide

HRID 1796759

Reaktionsgleichung

[C:1]1([CH:7]([C:26]2[CH:31]=[CH:30][CH:29]=[CH:28][CH:27]=2)[CH2:8][CH2:9][N:10]2[CH2:15][CH2:14][N:13]([C:16]3[CH:17]=[C:18]([C:22]([CH3:25])=[CH:23][N:24]=3)[C:19](O)=[O:20])[CH2:12][CH2:11]2)[CH:6]=[CH:5][CH:4]=[CH:3][CH:2]=1.[CH2:32]([NH:35][CH:36]1[CH2:41][CH2:40][CH2:39][CH2:38][CH2:37]1)[CH:33]=[CH2:34]>>[CH2:32]([N:35]([CH:36]1[CH2:41][CH2:40][CH2:39][CH2:38][CH2:37]1)[C:19](=[O:20])[C:18]1[C:22]([CH3:25])=[CH:23][N:24]=[C:16]([N:13]2[CH2:14][CH2:15][N:10]([CH2:9][CH2:8][CH:7]([C:1]3[CH:2]=[CH:3][CH:4]=[CH:5][CH:6]=3)[C:26]3[CH:31]=[CH:30][CH:29]=[CH:28][CH:27]=3)[CH2:11][CH2:12]2)[CH:17]=1)[CH:33]=[CH2:34]

Komponenten

Edukt 2

HCID 81115N-Allylcyclohexylamine

HCID 221806402-[4-(3,3-Diphenyl-1-propyl)piperazin-1-yl]-5-methylisonicotinic acid

Produkt 1

HCID 22180511N-Allyl-N-cyclohexyl-2-[4-(3,3-diphenyl-1-propyl)piperazin-1-yl]-5-methylisonicotinamideAusbeute 72,8 %

Versuchsvorschrift

Step (d) of Example 107 was repeated, except that the compound (50 mg) prepared in step (d) of Example 108 and allylcyclohexylamine (34 mg) were used as the starting compounds. Thus, the title compound (47 mg) was obtained.

Quellen und Nachweise

ORD-Eintrag: ord-8e757de0a427484089bebbeffbfb2f9f
Quelldatensatz: uspto-grants-2006_04
DOI: 10.6084/m9.figshare.5104873.v1
Patentnummer: US07030120B2

Verknüpfte Notizen

Wird geladen…